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LAY ABSTRACT
Patients with pure hereditary spastic paraplegia often 
have hip adductor spasticity, causing reduced gait width 
and a narrow base of support. In addition, they expe-
rience difficulties stepping sideways to recover from si-
deward balance perturbations. A small base of support 
and the presumed side-stepping difficulties probably in-
crease their risk of falling. Botulinum toxin type A injec-
tions are commonly used to reduce spasticity in patients 
with hereditary spastic paraplegia, but no studies have 
systematically investigated the effects of botulinum 
toxin type A in (with subsequent stretching of) the hip 
adductors on gait and balance. The results of this study 
indicate that, after botulinum toxin type A administra-
tion, there is an increase in comfortable gait speed and 
gait width. Furthermore, patients show improved reac-
tive stepping responses when the perturbation direction 
is known. It is concluded that botulinum toxin type A 
treatment and subsequent stretching of the hip adduc-
tors may improve gait and reactive lateral stepping in 
patients with pure hereditary spastic paraplegia.
Objective: To investigate the functional effects of bi-
lateral botulinum toxin A treatment and subsequent 
stretching of spastic hip adductors on gait and reac-
tive lateral stepping responses in patients with pure 
hereditary spastic paraplegia.
Design: Explorative pre-post intervention study. 
Patients: Twenty-five patients with pure hereditary 
spastic paraplegia.
Methods: Patients were treated with bilateral bo-
tulinum toxin A injections in the hip adductors and 
performed daily self-administered stretching exerci-
ses for 16 weeks. Before the intervention (T0), and 
6 (T1) and 16 (T2) weeks thereafter, gait width, gait 
speed, and leg angles at first stepping-foot contact 
after lateral balance perturbations were assessed, 
as well as the corresponding success rates of reac-
tive lateral steps. 
Results: Compared with baseline, gait width in-
creased by 12.6% and 9.7% and comfortable gait 
speed by 8.3% and 11.5% at T1 and T2, respecti-
vely. In known perturbation directions, leg angles 
increased by 5.9% at T1 and 8.0% at T2, while suc-
cess rates increased from 70% at baseline to 90% 
at T1 and T2. No effects were found for maximal gait 
speed or lateral stepping responses in unknown per-
turbation directions.
Conclusion: Bilateral botulinum toxin A treatment 
and subsequent stretching of the hip adductors may 
improve gait and reactive lateral stepping in patients 
with pure hereditary spastic paraplegia.
Key words: hereditary spastic paraplegia; botulinum toxin; 
balance control; gait.
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Patients with pure hereditary spastic paraplegia (HSP) show a slow, retrograde axonal degeneration 
of the corticospinal tract, which leads to bilateral pro-
gressive lower extremity spasticity. Although muscle 
strength and somatosensation are often also affected, 
the degree of paresis and sensory loss is usually milder 
than in other conditions with spastic paraparesis (e.g. 
spinal cord injury or multiple sclerosis) (1, 2). Hip 
adductor spasticity is often prominently present in 
patients with pure HSP. Besides loss of gait propulsion 
and deterioration of balance in the plane of progression 
(1, 3), patients are usually also affected by frontal-plane 
imbalance, to which hip adductor spasticity is sug-
gested to be an important contributing factor (4). This 
may be explained by spasticity of the hip adductors 
leading to forced, spontaneous narrowing of the base 
of support while standing and walking (“scissoring”). 
In addition, patients with HSP may experience difficul-
ties stepping sideways to recover from lateral balance 
perturbations, as the hip abductors have to overcome 
the involuntary activity of the spastic hip adductors. 
The small base of support in combination with the pre-
sumed difficulties in side-stepping probably increase 
the risk of falling in patients with HSP. 
Botulinum toxin type A (BTX-A) injections are 
commonly used for reducing spasticity in patients with 
HSP (2, 5–8), although BTX-A is still on off-label 
prescription in HSP for all commercially available 
toxins. BTX-A treatment of the hip adductors, calf 
muscles and hamstrings has been suggested to lead to 
functional improvements in balance and gait capacities 
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435Functional effects of botulinum toxin in patients with HSP
(4, 5). However, despite the high prevalence of hip 
adductor spasticity in patients with HSP, there are no 
studies that have systematically investigated the effects 
of BTX-A injections in these muscles, either on clinical 
indicators of spasticity, or with respect to balance and 
gait capacity. In a few previous studies with limited 
numbers of patients with HSP, the hip adductors were 
injected in some of the participants (n = 5–12), yet often 
in combination with other muscle groups (i.e. calves, 
tibialis posterior, iliopsoas and rectus femoris) (6, 8, 9). 
Furthermore, these studies did not include stretching 
exercises following BTX-A treatment, as recommended 
by international consensus (10). Hence, the specific 
effects of BTX-A injections in the hip adductors with 
subsequent stretching exercises remain to be established. 
This exploratory study focused on the effects of 
BTX-A injections in spastic hip adductors and subse-
quent stretching exercises in patients with pure HSP, 
using 2 primary outcomes: (i) gait width; and (ii) 
the quality of sideways reactive stepping responses 
following lateral balance perturbations. In addition, 
comfortable and fast gait speed, success rates of the 
lateral stepping responses, and various clinical (phy-
sical and functional) tests served as secondary outcome 
measures. The physiological effect of BTX-A usually 
reaches its maximum 6 weeks after the injections (11) 
and diminishes progressively until approximately 16 
weeks after the injections. Therefore, we hypothesized 
that reduced hip adductor tone would translate into 
improvements in both gait width and lateral stepping 
at 6 weeks post-treatment, whereas a reduction in these 
effects was expected at 16 weeks after treatment. 
METHODS
Participants
Participants were recruited from all patients with HSP and hip 
adductor spasticity known at the expert centre for genetic mo-
vement disorders of the Donders Institute for Brain, Cognition 
and Behaviour, Radboud University Medical Center, Nijmegen, 
The Netherlands. In addition, active recruitment took place 
through the national patient organization “Spierziekten Neder-
land”. Inclusion criteria were: (i) a “pure” form of autosomal 
dominant HSP (either genetically proven, or based on family 
history); (ii) 18 years of age or older; (iii) bilateral hip adductor 
spasticity (Modified Ashworth Scale (MAS) score 1–4); (iv) 
balance- and/or gait-related activity limitations in daily life; (v) 
able to walk > 50 m independently with (adapted) shoes and/or 
orthoses (but without walking aids, such as crutches or a wal-
ker); and (vi) comfortable gait velocity > 0.4 m/s. Participants 
were excluded if they had any cognitive impairment, or they 
had any comorbidity affecting their gait capacity. In addition, 
the final BTX-A treatment of the hip adductors should have 
been administered longer than 6 months before the first mea-
surement. Regular BTX-A treatments of other muscle groups 
should have been performed either within 3–4 weeks or longer 
than 4 months before the first measurement in order to have 
either an optimal or, otherwise, an absent effect of these prior 
injections during the study period. 
For participants recruited at the outpatient departments, all 
inclusion criteria were checked by the attending physician. 
Participants who responded to the recruitment letters via the 
patient organization were interviewed by telephone by the pri-
mary investigator to check inclusion criteria i, ii and iv, whereas 
inclusion criteria ii, v and vi were checked by a physiotherapist 
at the first visit for the study. Out of 75 patients, 25 fulfilled the 
inclusion criteria and were included. Their demographic and 
clinical characteristics are listed in Table I. 
Ethics statement
All subjects gave their written informed consent prior to partici-
pation. The study was approved by the regional medical-ethics 
committee and conducted in accordance with the Declaration 
of Helsinki. Due to lack of prior research on gait width and 
quality of reactive sidesteps in patients with HSP, no formal 
power calculation could be performed. Given the exploratory 
nature of the current study, a required number of 25 patients 
seemed optimal, feasible and justified, and was agreed upon by 
the medical ethics committee.
Intervention
Each participant was treated with bilateral BTX-A injections 
in the hip adductors by 1 of 3 rehabilitation physicians of our 
university hospital. A solution of 100 U Xeomin® (Botulinum 
toxin type A, Merz Pharmaceuticals GmbH, Frankfurt am Main, 
Germany) per 5 ml saline 0.9% was used. A dose of 150 or 200 
U per leg was injected, depending on the degree of hypertonia 
(Modified Ashworth Scale (MAS) 1: 150 U; MAS ≥ 2: 200 U). 
Table I. Patient characteristics before the intervantion (T0)
Characteristics
Sex, male/female, n 12/13
Gene, n
  SPG-4 12
  SPG-10 2
  SPG-17 1
  SPG-31 2
  AD, genotype not confirmed 8
Tibialis anterior, median (range)
MAS 0 (0–1)
MRC 5 (2–5)
Triceps surae, median (range)
MAS
knee extended 2.5 (1–4)
knee flexed 2.5 (0–4)
MRC 5 (2–5)
Hip adductors, median (range)
MAS 3 (1–4)
MRC 5 (2–5)
Hip abductors, median (range) 5 (2–5)
MRC
BBS, median (range) 49.5 (27–56)
Age, years, mean (range) 53.5 (26–72)
Hip abduction, mean (range)
ROM 38.8 (20.0–52.5)
6MWT, mean (range) 367.5 (196–515)
TUG, mean (range) 11.1 (6.3–23.0)
ABC, mean (range) 49.83 (17–95.3)
AD: autosomal dominant inheritance; MAS: Modified Ashworth Scale; MRC: 
Medical Research Council scale; BBS: Berg Balance Scale; ROM: range of motion; 
6MWT: 6-min Walk Test; TUG: Timed Up and Go test; ABC: Activities-specific 
Balance Confidence scale.
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436 B. J. H. van Lith et al.
The BTX-A was distributed over the gracilis, adductor magnus 
and adductor longus muscles according to Table II. Muscle 
selection was based on muscle volume and its moment arm 
with respect to the hip joint. Thigh length was measured from 
the pubic bone to the medial femoral condyle and thigh length 
percentages were calculated from the pubic bone (see Fig. 1). 
All BTX-A injections were placed under ultrasound guidance.
During the 16-week study period, participants were instructed 
to perform stretching exercises of the hip adductors (with the 
hips both flexed and extended) for approximately 10 min, 3 
times per day, and to log their exercises in a diary. The exercises 
were individually demonstrated and instructed by a physio-
therapist at the day of the BTX-A injections until each partici-
pant was able to correctly perform the exercises independently.
Outcome measures
Instrumented gait assessments. For instrumented gait as-
sessment, the GAITRite system was used (CIR Systems, Inc., 
Sparta, NJ, USA), which is a 4.88-m long carpeted walkway 
that contains pressure sensors that detect the position of each 
footfall (12). Participants started at one end of the GAITRite 
and were instructed to walk 3 times across the walkway with 
(adapted) shoes and/or orthoses at their preferred speed. Sub-
sequently, they walked 3 times across the walkway at their 
maximal speed without risking a fall. For each step, gait width 
was determined by the GAITRite system (and stored as “stride 
width”) and exported to Microsoft Excel. For each participant, 
the median gait width of all steps was calculated to avoid a 
disproportional influence of a single outlying step. Gait width 
was determined for both the preferred (primary outcome) and 
maximal gait speed. In addition, the mean preferred and mean 
maximal gait speed of the 3 trials was calculated.
Instrumented dynamic balance assessments. For instrumented 
dynamic balance assessments, the Radboud Falls Simulator was 
used (RFS). The RFS is a moveable platform (240 × 174 cm; 
BAAT, Enschede, The Netherlands (13)) that can translate in 
multiple directions. In this way, perturbations can be imposed 
that mimic natural situations. In this study, only sideways 
perturbations were used, where a leftward platform translation 
resulted in a rightward balance perturbation and vice versa. In 
the remainder of this text, we consistently refer to the direction 
of the balance perturbations. 
At the start of each measurement, participants were instructed 
to sustain all perturbations by making a single lateral step with-
out grabbing the handrails, while the perturbation direction was 
known to the participants. All participants wore a safety harness 
attached to the ceiling that prevented them from falling. In addi-
tion, a railing system was present at both sides that participants 
could grab in the case of a fall. At the first measurement (T0), 
participants were exposed to increasing perturbation intensities 
that started at 0.125 m/s2 and were increased by at least 0.125 
m/s2 between trials. The maximum perturbation intensity that 
each participant could successfully sustain with a single step at 
least once out of 3 trials (without falling or grabbing the railing 
system) defined the individual limit of stability. To familiarize 
them with the test situation, during the subsequent measure-
ments (T1 and T2), participants were again exposed to at least 
15 incremental perturbation intensities until their individual 
limits of stability were reached. 
During all measurements each participant was twice (ran-
domly) exposed to 5 leftward and 5 rightward perturbations at 
their individual limits of stability. During the first 10 perturba-
tions, the perturbation direction was known to the participant, 
whereas during the last 10 trials the perturbation direction was 
unknown. These 20 trials were used for statistical analysis.
During all balance assessments, kinematic data were recor-
ded by an 8-camera 3D motion analysis system (Vicon Motion 
Systems, Oxford, UK) at a sample rate of 100 Hz. Reflective 
markers were placed at anatomical landmarks according to the 
full-body PlugInGait configuration (14). For all trials in which 
the participant succeeded to make a sidestep following the 
perturbation, the leg angle (primary outcome) was calculated at 
the instant of stepping-foot contact, as the body configuration at 
step contact appears to critically determine the successfulness 
of balance recovery responses (15). The leg angle was defined 
as the angle between the absolute vertical and a line connecting 
the mid-pelvis and the ankle marker of the stepping foot. The 
medians of the 5 right and 5 left leg angles were calculated to av-
oid a disproportional influence of a single outlying value. These 
medians were averaged for each person into a single leg angle 
score for the perturbations with known and unknown directions 
separately. Furthermore, the success rates of the lateral stepping 
responses were calculated for the perturbations with known and 
unknown directions separately. A trial was scored as successful 
if the participant maintained balance with a single sidestep.
Physical tests. Muscle strength of the hip adductors and hip 
abductors was assessed with the Medical Research Council 
(MRC) scale (0–5), with lower scores indicating more muscle 
weakness (16). Muscle tone of the hip adductors was assessed 
using the MAS (0–5), with higher scores indicating more hy-
pertonia (17). Furthermore, passive range of motion (ROM) on 
Table II. Distribution of botulinum toxin per leg
 
Percentage thigh 
length*, %
Units/ml
MAS 1 MAS ≥ 2
Gracilis 15 15/0.75 20/1.00
35 15/0.75 20/1.00
60 15/0.75 20/1.00
Adductor magnus 15 30/1.50 40/2.00
35 30/0.75 40/2.00
Adductor longus 15 30/1.50 40/2.00
 35 15/0.75 20/1.00
*Upper leg length was calculated from pubis bone to medial femoral condyle. 
Thigh-length percentages were expressed from pubis.
Fig. 1. Schematic view of injection locations in percentages thigh length 
from the pubic bone to the medial femoral condyle. At the indicated 
thigh lengths, botulinum toxin (BTX) was injected into the adductor 
longus (L), adductor magnus (M) and gracilis (G).
www.medicaljournals.se/jrm
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437Functional effects of botulinum toxin in patients with HSP
hip abduction was measured using a goniometer. All outcomes 
were averaged for both sides into a single score.
Functional tests. Functional balance was assessed barefooted 
with the Berg Balance Scale (BBS, range 0–56) (18). The Timed 
Up and Go (TUG test) (19) was performed with (adapted) shoes 
and/or orthoses, but without other walking aids. Endurance was 
assessed with the 6-min Walk Test (6MWT) (20) during which 
all walking aids were allowed. Lastly, the Activities-specific 
Balance Confidence (ABC) scale (21) was obtained as a sub-
jective measure of mobility and balance. 
Procedure
All outcome measurements were performed on the day of 
treatment prior to the injections (baseline; T0), 6 (± 1) weeks 
after treatment (T1), and 16 (± 1) weeks after treatment (T2). 
T1 was set at 6 weeks after treatment, because at this time-point 
the physiological effects of BTX-A on spasticity were expected 
to have reached a maximum (11). The effects of BTX-A were 
expected to diminish progressively until approximately 16 
weeks after the injections. Hence, T2 was set at 16 weeks post-
treatment to test the possible presence of a long-term effect of 
the combined treatment. The instrumented assessments were 
taken by the primary investigator. All other tests were assessed 
by an independent physiotherapist. 
Statistical analysis
All instrumented (parametric) outcome measures were tested 
using repeated-measures analysis of variance (ANOVA). The 
primary outcomes gait width and sidestep leg angle were tested 
using time (T0 – T1 – T2) as within-subjects factor. For gait 
width and gait speed, also gait condition (preferred – maximal) 
was introduced as a within-subjects factor. Bonferroni corrected 
post-hoc tests were applied in the case of a significant main effect 
of time. All other (non-parametric) outcome measures (physical 
and functional tests) were analysed with a Friedman’s test using 
time (T0 – T1 – T2) as a within-subject factor. Wilcoxon’s tests 
were used for post-hoc comparisons in the case of a significant 
time effect. All statistical analyses were performed using IMB 
SPSS Statistics Version 22 for Windows. The α-level was set at 
0.05 for all analyses, with no adjustment for multiple outcomes. 
RESULTS
Participants
From the total of 25 patients included in the study, 3 
patients were lost between the first (T0) and second 
measurements (T1): 1 patient experienced increasing 
shoulder complaints that were already present before 
the first visit. One patient was lost due to spontaneous 
severe back pain, which had also repeatedly occurred 
in the past. A third patient left the study due to perso-
nal circumstances. No other adverse events occurred 
during the study.
Instrumented gait assessments
Table III summarizes the group results for all measu-
rements. There was a significant time effect on gait 
width (F(2,42) = 6.143, p = 0.005). Gait width increased 
by 12.6% from baseline to T1 (p = 0.021), and this im-
provement persisted at T2 (9.7%; p = 0.022) (see Fig. 
2a). There was no effect of gait condition on gait width 
(F(1,21) = 1.229, p = 0.280), nor was there a significant 
time × gait condition interaction (F(2,42) = 1.081, 
p = 0.349). 
Table III. Outcomes measures 
Test
Before intervention
(T0)
After 6 weeks
(T1)
After 16 weeks
(T2)
Friedman’s test 
or repeated-
measures
ANOVA p-value
GaitRite, mean (SD) [95% CI]
Gait width – preferred speed, cm 10.7 (5.8) [8.1–13.2] 11.8 (6.0) [9.1–14.4] 11.3 (5.7) [8.7–13.8]
F(2,42) = 6.143 0.005a
Gait width – maximal speed, cm 10.0 (6.0) [7.4–12.7] 11.5 (6.1) [8.8–14.2] 11.2 (5.8) [8.7–13.8]
Comfortable gait speed, m/s 0.96 (0.25) [0.85–1.07) 1.04 (0.26) [0.93–1.16] 1.07 (0.28) [0.94–1.20] F(2,42) = 15.265 < 0.001b
Maximal gait speed, m/s 1.31 (0.41) [1.14–1.50] 1.33 (0.35) [1.17–1.48] 1.36 (0.41) [1.18–1.54] F(2,42) = 1.140 0.330
Radboud Falls Simulator
Leg angle – known dir, mean (SD) [95% CI] 18.7 (4.1) [16.7–20.7] 19.8 (3.8) [17.9–21.6] 20.2 (4.1) [18.2–22,1] F(2,32) = 8.568 0.001a
Leg angle – unknown dir, mean (SD) [95% CI] 19.1 (4.7) [16.3–22.0] 19.3 (4.7) [16.5–22.2] 19.4 (5.2) [16.3–22.6] F(2,24) = 0.107 0.899
Success rates – known dir, %, median [IQR] 70.0 [45.0] 90.0 [30.0] 90.0 [45.0] χ2(2, n = 21) = 12.559 0.002c
Success rates – unknown dir, %, median [IQR] 25.0 [55.0] 35.0 [72.5] 45.0 [70.0] χ2 (2, n = 22) = 4.388 0.111
Clinical assessments
MAS – hip adductors, median [IQR] 2.5 [1.3] 1.0 [1.5] 1.8 [1.0] χ2(2, n = 22) = 33.890 < 0.001d
MRC – hip adductors, median [IQR] 5.0 [0.0] 4.0 [1.0] 5.0 [0.3] χ2(2, n = 22) = 15.800 < 0.001e
MRC – hip abductors, median [IQR] 5.0 [0.1] 5.0 [1.0] 5.0 [0.0] χ2(2, n = 22) = 4.957 0.084
ROM – hip abduction, mean (SD) [95% CI] 38.8 (9.4) [34.6–42.9] 50.7 (12.5) [45.2–56.2] 45.0 (10.8) [40.2–49.8] F(2,42) = 31.613 < 0.001f
Other functional tests
BBS, median [IQR] 49.5 [10.0] 51.5 [9.0] 51.0 [7.8] χ2(2, n = 22) = 4.031 0.133
TUG, s, mean (SD) [95% CI] 10.6 (3.8) [8.6–12.6] 10.7 (4.2) [8.6–12.9] 10.5 (4.3) [8.3–12.7] F(2,42) = 0.198 0.821
6MWT, s, mean (SD) [95% CI] 367.5 (87.9) [322.3–412.7] 376.0 (95.8) [327.0–425.2] 382.1 (95.2)[333.2–431.0] F(2,32) = 2.498 0.098
ABC scale, %, mean (SD) [95% CI] 55.0 (21.85) [43.8–66.2] 54.7 (22.8) [43.0–66.4] 51.5 (23.7) [39.3–63.6] F(2,42) = 2.048 0.142
aT0<T1/T2, T1 = T2; bT0<T1<T2; cT0<T1, T0 = T2, T1 = T2; dT0>T2>T1; eT0/2>T1, T0 = T2; fT0<T2<T1. MAS: Modified Ashworth Scale; MRC: Medical Research 
Council scale; ROM: range of motion; BBS: Berg Balance Scale; TUG: Timed Up and Go test; 6MWT: 6-min Walk Test; ABC: Activities-specific Balance Confidence 
scale; dir: direction.
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438 B. J. H. van Lith et al.
There was also a significant time effect on gait speed 
(F(2,42) = 5.458, p = 0.008) as well as a significant 
time × gait condition interaction (F(2,42) = 5.399, 
p = 0.008). Compared with baseline, the preferred gait 
speed had increased by 8.3% at T1 (p = 0.001) and by 
11.5% at T2 (p < 0.001). In contrast, no significant 
changes from baseline were observed in the maximal 
gait speed (Fig. 2b). 
Instrumented balance assessments
Changes in leg angles across time could only be statisti-
cally tested if side steps were made at all measurements 
(T0–T2). As some participants failed to make any side 
steps (i.e. only made cross steps) or grabbed the rai-
ling system before stepping, a total of 19 participants 
could be included in the analysis of trials with known 
perturbation direction and 13 in the analysis of trials 
with unknown directions. The mean limit of stability 
was 2.135 m/s2 (range 0.375–4.375 m/s2).
For the known direction perturbations, the leg 
angle showed a main effect of time (F(2,36) = 12.053, 
p < 0.001). There was an increase of 5.9% in leg angle 
from baseline to T1 (p = 0.003), which persisted at T2 
(8.0%; p = 0.001). In contrast, leg angle for the unk-
nown direction perturbations did not show a significant 
effect of time (F(2,24) = 0.107, p = 0.899) (see Fig. 3a). 
For the known direction perturbations, there was a 
significant effect of time on success rate (χ2(2) = 12.559, 
p = 0.002). Compared with the 70% success rate at ba-
seline, participants were more successful at T1 (90%; 
p = 0.007), which result tended to persist at T2 (90%; 
p = 0.075). For the unknown direction perturbations, 
no significant effects of time were found (χ2(2) = 4.388, 
p = 0.111) (see Fig. 3b).
Physical tests
Hip adductor muscle tone showed a significant time 
effect (χ2(2) = 33.890, p < 0.001). The MAS scores 
decreased from baseline to T1 (p < 0.001), and subse-
quently increased from T1 to T2 (p = 0.001), although 
they did not reach the baseline values (T0 vs T2, 
p = 0.001). Hip adductor muscle strength also showed a 
Fig. 2. (a) Gait width and (b) gait speed at 3 measurements (T0, T1, T2) for preferred and maximal gait speed (gait condition). *Indicates significant 
post-hoc effects of time for gait width. #Indicates significant post-hoc effects of time on preferred gait speed.
Fig. 3. (a) Leg angle and (b) success rate at 3 measurements (T0, T1, T2) for known and unknown perturbation directions. #Indicates significant 
post-hoc effects of time in known perturbation directions. *Indicates significant effect of time.
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significant effect of time (χ2) = 15.800, p < 0.001), as the 
MRC scores decreased from baseline to T1 (p = 0.005), 
and increased from T1 to T2 (p = 0.003) to baseline 
values (T0 vs T2, p = 0.480). Hip abductor muscle 
strength did not significantly differ between the 3 
measurements (χ2(2) = 4.957, p = 0.084). Furthermore, 
there was a significant time effect on hip abduction 
ROM (F(2,42) = 31.613, p < 0.001), which increased 
from baseline to T1 (p < 0.001) and decreased from T1 
to T2 (p = 0.001), although it was still above baseline 
values at T2 (T0 vs T2, p < 0.001).
Functional tests
Because the 6MWT was too demanding for 5 parti-
cipants, the analysis was performed on the remaining 
17 participants. This analysis showed no signifi-
cant effect of time on the 6MWT (F(2,32) = 2.498, 
p = 0.098). Likewise, the BBS (χ2(2) = 4.031, p = 0.133), 
TUG (F(2,42) = 0.198, p = 0.821), and ABC scale 
(F(2,42) = 2.048, p = 0.142) also did not show signifi-
cant time effects.
DISCUSSION
The aim of this study was to evaluate the effects of 
BTX-A treatment and subsequent stretching of the hip 
adductors on gait and balance capacities in patients 
with pure HSP. The results support our hypothesis 
that bilateral BTX-A injections in, and subsequent 
stretching of, the hip adductors improve both gait width 
and lateral stepping responses in known perturbation 
directions coinciding with reduced hip adductor tone 6 
weeks after treatment compared with baseline. These 
functional effects were retained, although some recur-
rence of hip adductor muscle tone was found 10 weeks 
later. In addition, comfortable gait speed increased 6 
weeks post-injections, which effect was even a little 
stronger after 16 weeks. In contrast, maximal gait speed 
and lateral stepping responses in unknown perturbation 
directions did not respond to the treatment, nor did 
other functional tests (BBS, TUG, 6MWT, ABC scale). 
Besides a prolonged reduction in hip adductor 
muscle tone lasting up to 16 weeks after treatment, we 
observed a similar and substantial improvement in hip 
abduction ROM (on average 13.3°) and a temporary 
reduction of hip muscle strength (on average 1 point 
on the MRC scale, 6 weeks after treatment). These 
findings are in line with several previous studies (2, 3, 
5, 6, 8, 9, 11). The mean improvement of muscle tone 
at 6 weeks post-injections was 1.5 point on the MAS, 
which can be considered substantial and clinically re-
levant (22). Interestingly, the observed temporary loss 
of muscle strength did not seem to have a detrimental 
effect on balance and gait capacities, since functional 
tasks improved (or remained stable) 6 weeks after 
treatment. This result is in agreement with a previous 
study from our group (2) and suggests that loss of 
muscle strength after BTX-A injections in spastic 
muscles is probably of relatively short duration and 
without noticeable functional disadvantage. 
The observed improvement in gait width was, on 
average, 1.1 and 1.5 cm for comfortable and maximal 
walking speed, respectively, and was probably the 
direct result of reduced hip adductor tone and impro-
ved hip abduction ROM. Remarkably, this effect was 
found even though comfortable gait speed improved 
in parallel. It is conceivable that a higher gait speed 
might coincide with faster leg swing and, thus, ag-
gravate velocity-dependent hip adductor spasticity, 
but this effect apparently did not occur. Instead, the 
reason why comfortable gait speed improved may be 
that reduced hip adductor tone allowed patients to make 
larger and/or faster steps. In a prior study of patients 
with spastic paraparesis of various origins, BTX-A 
injections in the hip adductors also led to increased gait 
velocity (23). In addition, previous studies of patients 
with HSP in which hip adductors were injected with 
BTX-A in combination with other muscle groups also 
showed increased gait speed (6, 8, 9). These findings 
have important clinical implications as reduced sponta-
neous gait speed is one of the most frequent problems 
reported by patients with HSP (24). Notably, maximal 
gait speed did not improve after treatment, which is in 
agreement with the notion that the hip adductors are 
not the key muscles for gait propulsion (25). Neverthe-
less, gait width during walking at maximal gait speed 
improved even more strongly than during comfortable 
walking, indicating the robustness of the treatment ef-
fects on widening the base of support while walking. 
The observed effect size for gait width in this study 
may seem small, but it constitutes a 10–15% increase 
compared with baseline. Hence, the observed increase 
in gait width of 1.1–1.5 cm may be clinically relevant 
in terms of improved frontal-plane balance, but this 
conclusion needs to be supported by future studies.
To our knowledge, the effects of bilateral BTX-A in-
jections on reactive lateral stepping responses have not 
been investigated previously. In the present study, we 
only observed beneficial effects on stepping responses 
to perturbations in known directions. Interestingly, no 
improvements in stepping leg angle or success rate were 
observed upon perturbations in unknown directions. As 
hip adductor spasticity decreases, less muscle activity of 
the hip abductors is supposedly needed to make a lateral 
step. One explanation for the observed discrepancy bet-
ween known and unknown perturbation direction may 
be that the individual maximal perturbation intensity at 
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baseline was based on tests with a known perturbation 
direction. As a consequence, the perturbation intensities 
might have been too high for the participants following 
perturbations in unknown directions. This may also 
(partly) explain the much lower number of participants 
able to sustain perturbations with unknown compared 
with known directions. Another reason might be that 
reactive steps following unexpected perturbations are 
relatively strongly influenced by delayed postural re-
sponses that occur in patients with HSP (4, 26), because 
patients cannot compensate by an anticipatory “central 
set” if the direction is unknown. Nevertheless, the 
improved balance capacity following perturbations in 
known directions suggests that hip adductor spasticity 
indeed impairs the quality of lateral stepping responses 
and, thus, is a relevant treatment target from a frontal-
plane balance perspective.
The fact that the beneficial effects on muscle tone, 
gait width, comfortable gait velocity, lateral balance 
persisted until 16 weeks after treatment seems to chal-
lenge the common opinion that the biological effects 
of BTX-A have worn off after this time interval. It 
may, therefore, be that the stretching component of the 
treatment protocol was responsible for the observed 
long-term effects.
Study limitations and future perspectives
A limitation of the present exploratory study in pa-
tients with HSP is the relatively small sample size 
and the lack of a control condition, while the rather 
stringent inclusion and exclusion criteria limit the 
generalizability of our findings. Nevertheless, this 
study provides indications for the beneficial effects 
of bilateral BTX-A injections in the adductor longus, 
adductor magnus and gracilis muscles and subsequent 
stretching of these muscles on gait width, comfortable 
gait speed, and reactive lateral stepping in known 
perturbation directions, whereas maximal gait speed, 
gait endurance, and clinical balance scores appear to 
be less responsive in these patients. Future research 
should preferably be multi-centred to increase the 
number of participants and use a randomized controlled 
design. Gait width and gait speed would be valuable 
and responsive outcome measures in such trials. The 
instrumented balance assessments used in the present 
study are, however, less suitable for multi-centre stu-
dies as they require further development of clinically 
affordable systems. Clinically applicable assessments 
to validly test the quality of (lateral) reactive stepping 
responses are therefore urgently needed. As HSP is a 
chronic and progressive condition, it would also be 
relevant to conduct longitudinal, comparative cohort 
studies to investigate whether repetitive cycles of BTX-
A treatment of spastic hip adductors improve lifetime 
functional ambulation prognosis in these patients. 
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